Table 2.

Characteristics of Participating Studies and Drug/Dose Combinations

		Study-Level Statistics
Study and Drug/Dose	n	Clinical Events, n	% Female	% Black	% NYHA III/IV	% CTD
ARIES-1		10	84	7.3	65	31
Ambrisentan 5 mg	67
Ambrisentan 10 mg	67
Placebo	67
ARIES-2		20	74	0	54	32
Ambrisentan 2.5 mg	64
Ambrisentan 5 mg	63
Placebo	65
BREATHE-1		9	79	7.1	100	22
Bosentan 125 mg	75
Bosentan 250 mg	70
Placebo	69
AIR		41	67	1.5	100	23
Iloprost	101
Placebo	101
STRIDE-1		7	79	8.1	67	24
Sitaxsentan 100 mg	55
Sitaxsentan 300 mg	63
Placebo	60
STRIDE-2		8	77	13.1	63	29
Sitaxsentan 50 mg	61
Sitaxsentan 100 mg	62
Placebo	62
STRIDE-4		2	84	6.7	39	15
Sitaxsentan 50 mg	32
Sitaxsentan 100 mg	32
Placebo	34
SUPER		17	76	2.6	61	30
Sildenafil 20 mg	68
Sildenafil 40 mg	65
Sildenafil 80 mg	71
Placebo	65
PHIRST		39	78	9.7	67	24
Tadalafil 2.5 mg	79
Tadalafil 10 mg	79
Tadalafil 20 mg	81
Tadalafil 40 mg	75
Placebo	81
Treprostinil		45	81	5.3	7	19
Treprostinil	233
Placebo	237

NYHA indicates New York Heart Association; CTD, connective tissue disease; ARIES, Ambrisentan in Pulmonary Arterial Hypertension, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Efficacy Studies; BREATHE, Bosentan: Randomized Trial of Endothelin receptor Antagonist Therapy; AIR, Aerosolized Iloprost Randomized; STRIDE, Sitaxsentan To Relieve Impaired Exercise; SUPER, Sildenafil Use in Pulmonary Hypertension; and PHIRST, Pulmonary Arterial Hypertension and Response to Tadalafil.